Severe deficiency of TFPI K1 domain is compatible with embryonic development, adult survival, and reproductive functions in mice.
Severely TFPI K1–deficient mice display elevated TAT levels, renal fibrosis, and increased susceptibility to TF-mediated pulmonary embolism.
Tissue factor pathway inhibitor (TFPI) is a serine protease with multiple anticoagulant activities. The Kunitz1 (K1) domain of TFPI binds the active site of factor VIIa and is required for inhibition of tissue factor (TF)/factor VIIa catalytic activity. Mice lacking TFPI K1 domain die in utero. TFPI is highly expressed on trophoblast cells of the placenta. We used genetic strategies to selectively ablate exon 4 encoding TFPI K1 domain in the embryo, while maintaining expression in trophoblast cells. This approach resulted in expected Mendelian frequency of TFPI K1 domain–deficient mice. Real-time polymerase chain reaction confirmed 95% to 99% genetic deletion and a similar reduction in transcript expression. Western blotting confirmed the presence of a truncated protein instead of full-length TFPI. Mice with severe TFPI K1 deficiency exhibited elevated thrombin-antithrombin (TAT) levels, frequent fibrin deposition in renal medulla, and increased susceptibility to TF-induced pulmonary embolism. They were fertile, and most lived normal life spans without any overt thrombotic events. Of 43 mice observed, 2 displayed extensive brain ischemia and infarction. We conclude that in contrast to complete absence of TFPI K1 domain, severe deficiency is compatible with in utero development, adult survival, and reproductive functions in mice. Inhibition of TFPI activity is being evaluated as a means of boosting thrombin generation in hemophilia patients. Our results show that in mice severe reduction of TFPI K1 activity is associated with a prothrombotic state without overt developmental outcomes. We note fibrin deposits in the kidney and rare cases of brain ischemia.
Tissue factor pathway inhibitor (TFPI) is a serine protease inhibitor that regulates multiple steps in thrombin generation.1 It is an efficient inhibitor of tissue factor (TF)/factor VIIa (fVIIa) catalytic activity. TFPI is highly expressed on trophoblast and endothelial cells of the placenta and in embryonic and adult tissues.2-5 It is alternatively spliced and produced in 2 major isoforms in humans, TFPIα and TFPIβ. The longer isoform, TFPIα, consists of an acidic N-terminal region followed by 3 Kunitz-type domains, and a basic C-terminal region. The first and second Kunitz domains, respectively, bind the active sites of fVIIa and fXa,6 and the third Kunitz-type domain binds protein S.7,8 The C-terminal region of TFPIα contains a stretch of amino acids that bind fVa and promote inhibition of early forms of the prothrombinase complex.1,9,10 TFPIβ lacks the third Kunitz domain and has an alternatively spliced C-terminal region that encodes a glycosylphosphatidyl inositol anchor, allowing surface association. The 2 isoforms differ in their distribution. In mice, both TFPIα and TFPIβ are expressed in the placenta. TFPIα is also expressed by megakaryocytes, stored in platelets, and released upon platelet activation. Both α and β isoforms are expressed in mouse embryos, whereas adult mouse tissues predominantly express the TFPIβ isoform.5 Mice also produce a third TFPI isoform called TFPIγ. TFPIγ is a soluble form of TFPI containing only the first and second Kunitz domains and is widely expressed in mouse tissues. However, the production of TFPIγ protein has not been well characterized.11
There are no documented cases of complete TFPI deficiency in humans. Reduced plasma levels are reported in FV-deficient patients12,13 and in patients lacking low-density lipoprotein, a carrier of TFPI in plasma.14 In mice, global deletion of exon 4 that encodes the K1 domain was reported to result in embryonic lethality. About 60% embryos were reported to die between 9.5 and 11.5 days of development with signs of yolk sac hemorrhage. The remaining embryos showed hemorrhage, particularly in the head, spine, and tail, accompanied by pallor. No live pups were found at birth.15 Thus, the most dramatic drop in the viability of TFPI K1 null embryos was observed soon after the formation of the definitive placenta. An independent study reported disruption of vascular network, thrombosis, and hemorrhage in placentas of late gestational TFPI_K1−/− embryos.16 Based on these reports, we postulated a critical role of extraembryonic TFPI in inhibiting TF activity. The objectives of this study were to determine if maintaining extraembryonic expression allows in utero development of TFPI K1 domain-null embryos and to examine the effect of TFPI K1 deficiency on embryos and adult mice.
Animal experiments were conducted following standards and procedures approved by the Animal Care and Use Committee of the Medical College of Wisconsin. TFPI exon 4 floxed mice (stock number 017603; Jackson Laboratory, Bar Harbor, ME) and Meox2Cre mice (Stock number 003755; Jackson Laboratory) have been previously described.17-19 All mouse strains were used and maintained in C57BL/6 genetic background. Genetic combinations were generated by breeding and identified by polymerase chain reaction (PCR)–based genotyping of tissue obtained by tail biopsy. Primers described in original referenced publications or by Jackson Laboratory were used.
Analysis of pregnancies
The stage of pregnancies was assessed from days post coitum (dpc), assuming midday of plug as 0.5 dpc. Methods used for embryo dissection, genotyping, and phenotyping have been previously described.20
Histology and immunohistochemistry
Organs were fixed in zinc formalin, embedded in paraffin, and cut into 4-μm sections. Prior to embedding, the placentas were marked with ink to identify the center. Slides were stained with hematoxylin & eosin, Masson’s trichrome, or Carstairs’ stain (Electron Microscopy Sciences, Hatfield, PA) using standard protocols. For immunostaining, antigen retrieval was performed in citrate buffer pH 6.0, and antibodies that recognize macrophage marker F4/80 or neutrophil marker Ly-6G (ThermoFisher Scientific, Waltham, MA) were used.
Real-time PCR for genomic DNA and comparative expression analysis
Genomic DNA or total RNA was extracted from embryos or organs of adult mice. Total RNA was extracted using TRIZOL reagent (ThermoFisher Scientific) and reverse transcribed with iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA). Real-time quantitative PCR (qPCR) was performed with IQ SYBR Supermix (Bio-Rad) or a probe-based assay with primers designed to identify the presence of intact exon 4-5 (forward 5′-TCTGTTGCTTAGCCTTGTTCC-3′ and reverse 5′-CCATCATCTGCCTTCATTGC-3′) (expected product size 123 bp) or exon 7-8 (forward 5′-ACGTAGTCACTCATCTGTACCT-3′ and reverse 5′-CAACCGCAACAACTTTGAAAC-3′) (expected product size 102 bp), using actin as internal control gene for normalization (forward 5′-AGGTCTTTACGGATGTCAACG-3′ and reverse 5′-ATTGGCAACGAGCGGTT-3′) (Integrated DNA Technologies, Inc, Skokie, IL). Real-time qPCR with genomic DNA was performed with IQ SYBR Supermix (Bio-Rad) using TFPI forward 5′-AAGGGAACGAGAACCGATTT-3′ and reverse 5′-AGAAACAACAGTGGGCCAGA-3′primers that amplify the intact gene but not exon 4–deleted gene. Internal positive controls for normalization were generated with forward 5′-CTAGGCCACAGAATTGAAAGATCT-3′ and reverse 5′-GTAGGTGGAAATTCTAGCATCATCC-3′ primers. Following real-time analysis, the end products were separated on 1.8% agarose gels containing ethidium bromide and visualized by UV transillumination.
Western blot analysis
Mice were perfused with phosphate-buffered saline prior to organ harvest. Mouse tissues were weighed, minced, lysed, and centrifuged as previously described to remove cellular debris.5 For plasma sample preparation, 9 parts of blood was collected from the inferior vena cava into 1 part of 3.8% sodium citrate and 183 µg/mL corn trypsin inhibitor. Plasma was separated by centrifugation at 200g for 5 minutes and then again at 800g for 10 minutes at room temperature. TFPI was precipitated from tissue lysates and plasma samples using bovine fXa coupled resin (ThermoFisher Scientific) and analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and western blot using a rabbit anti-mouse TFPI polyclonal antibody. To allow a quantitative comparison, the weight or volume of TFPI K1–deficient and wild-type (WT) tissue or plasma samples, the volume of fXa coupled resin, and the volumes loaded on gels for each sample were kept equal.
Thrombin-antithrombin (TAT) levels and activity assays
Plasma TAT levels were measured using AssayMax Mouse TAT Elisa Kit (Assaypro LLC, St. Charles, MO) according to the manufacturer’s instructions. Plasma was prepared by collecting 600 μL blood from the inferior vena cava into 50 μL of 16.5 mg/mL EDTA, followed by centrifugation at 1500g for 15 minutes. For thrombin generation assays, blood was drawn in sodium citrate, and platelet-poor plasma was diluted threefold before using it with Technothrombin TGA (Diapharma, West Chester, OH) as per the manufacturer’s instructions. TF (RecombiPlasTin 2G; Instrumentation Laboratory, Bedford, MA) was reconstituted following the manufacturer’s directions and used at a final dilution of 1:6000 for technothrombin assays.
TF-induced pulmonary embolism
TF (Recombiplastin 2G; Instrumentation Laboratory) was reconstituted according to the manufacturer’s directions. Mice were weighed and anesthetized, and the inferior vena cava was exposed. A 1:80 dilution of TF (diluted in phosphate-buffered saline) was IV injected using a 26-gauge needle at a dose of 5 µL/g body weight. Time to death was measured as time to the onset of respiratory arrest that lasted at least 2 minutes. All experiments were terminated at 30 minutes. The dose of TF used was selected by titration to be the lowest dose at which 80% of WT mice survived beyond the 30-minute observation period. A previously described Evan’s blue (1% in saline) perfusion assay and scoring system was used as an independent measure of lung vascular occlusion.21 One hundred percent of perfused lungs turned blue (score 0; no perfusion defect), whereas in the complete absence of perfusion, the lungs remained pink (score 4). Intermediate levels of perfusion were ranked as 1, 2, and 3 in the order of decreasing perfusion.
The χ2 goodness-of-fit (GOF) test was used to determine deviation from expected Mendelian proportions. Exact binomial 95% confidence intervals (CIs) were computed where appropriate. The Student t test (2 tailed with unequal variance) was used for comparing TAT values and Evan’s blue perfusion assay scores. Kaplan-Meier survival and Log-rank test were performed using SAS version 9.4 (SAS Institute, Cary, NC) and SPSS version 20.0 (IBM Corp, Armonk, NY). Two-proportion z test was used to compute P values for surviving proportions in TF-induced pulmonary embolism assay. P < .05 was used to establish significance for all experiments.
TFPI Kunitz1 (K1) deficiency is compatible with embryonic development if placental expression is maintained
In the current work, we used the Meox2Cre strain18 to conditionally delete exon 4 of TFPI gene in epiblast-derived tissues while maintaining expression in trophoblast and primitive endoderm cells of the placenta (supplemental Figure 1). We have previously confirmed the excision pattern of Meox2Cre by using a double fluorescent Cre reporter mouse.22 Meox2Cretg/+ male mice were mated to TFPI_K1Lox/Lox female mice to generate Meox2Cretg/+ TFPI_K1δ/+ male mice. In a second cross, these were mated to TFPI_K1Lox/Lox female mice. Equal frequencies of TFPI_K1Lox/+, TFPI_K1Lox/δ, Meox2Cretg/+ TFPI_K1δ/+ (abbreviated as TFPI_K1δ/+), and Meox2Cretg/+ TFPI_K1δ/δ (abbreviated as TFPI_K1δ/δ) genotypes are expected in progeny from this cross. The results indeed showed equal representation of these genotypes among embryos examined at 12.5 and 15.5 dpc and pups at weaning age (no significant difference was observed from expected Mendelian frequencies as determined by χ2 GOF test, P = .514) (Table 1). TFPI_ K1δ/δ pups were born at 22% frequency with 95% CI of 16 to 28%. These results are in striking contrast to global TFPI K1 domain deletion, which results in complete embryonic lethality with no TFPI_K1−/− pups surviving to wean.15,16 TFPI_K1δ/δ embryos from epiblast-specific deletion were healthy in appearance with no obvious signs of bleeding or hemorrhage (Figure 1A-B).
|Stage .||TFPI K1Lox/+ .||TFPI K1Lox/δ .||TFPI K1δ/+ .||TFPI K1δ/δ .||No. aborted .||No. analyzed (pregnancies) .|
|12.5 dpc||6||11||13||6||4||40 (5)|
|15.5 dpc||4||4||9||5||3||22 (4)|
|Wean (∼4 wk)||51||46||57||43*||—||197 (33)|
|Stage .||TFPI K1Lox/+ .||TFPI K1Lox/δ .||TFPI K1δ/+ .||TFPI K1δ/δ .||No. aborted .||No. analyzed (pregnancies) .|
|12.5 dpc||6||11||13||6||4||40 (5)|
|15.5 dpc||4||4||9||5||3||22 (4)|
|Wean (∼4 wk)||51||46||57||43*||—||197 (33)|
Pregnancy outcome was analyzed at 12.5 dpc, at 15.5 dpc, and at wean ∼4 wk of age. TFPI_K1δ/δ mice survive embryonic development and are born at near expected frequency. No significant difference was observed from expected proportions at the time of wean, based on χ2 GOF test (P = .514). Number aborted could not determined when analysis was done at the time of weaning and is indicated by a dash.
TFPI_K1δ/δ pups were born at 22% frequency (95% CI 16% to 28%).
Placentas of TFPI K1–deficient embryos do not show thrombotic or hemorrhagic abnormalities
We crossed TFPI_K1δ/+ male mice to WT C57BL/6 female mice to generate TFPI_K1+/− animals. These animals contain a WT allele of TFPI and an exon 4–deleted allele in all cells. To replicate previously published observations with global deletion of TFPI K1 domain in mice, we examined 7 timed pregnancies from TFPI_K1+/− intercrosses. We observed 6 TFPI_K1+/+, 12 TFPI_K1+/−, 2 TFPI_K1−/−, and 7 aborted embryos (4 genotyped as TFPI_K1−/−) at 11.5 and 8 TFPI_K1+/+, 9 TFPI_K1+/−, 3 TFPI_K1−/−, and 3 aborted embryos (all genotyped as TFPI_K1−/−) at 18.5 dpc. Thus, 58% of TFPI_K1−/− embryos (7 out of 12) were found dead: 4 out of 6 at 11.5 and 3 out of 6 at 18.5. Of the 2 live embryos at 11.5, one showed intracranial hemorrhage, and both showed reduced elaboration of fetoplacental vasculature (Figure 2). Macroscopic placental hemorrhage was observed in another TFPI_K1−/− embryo at 18.5 dpc (not shown). In contrast to these observations, the placentas corresponding to TFPI_K1δ/δ embryos (generated using Meox2Cre) were grossly normal in appearance and in histology with no overt signs of excessive thrombotic lesions, bleeding, or abnormalities (Figure 1C-F). Thus, maintaining full-length TFPI expression in uteroplacental circulation corrected the placental abnormalities present in global TFPI K1 knockout mice.
Expression of truncated TFPI RNA and protein in TFPI K1 domain–deficient mice
To verify the efficiency of CRE recombinase–mediated excision of floxed exon 4, we performed real-time qPCR on reverse transcribed RNA extracted from whole embryos. The results demonstrated 95% to 99% reduction in exon 4 containing RNA in whole embryos (Figure 3A). We also conducted real-time qPCR on reverse transcribed RNA extracted from liver and kidneys of adult animals using primers encompassing exons 4 to 5. Results showed 95% to 99% reduction of exon 4 containing RNA. These results were visually confirmed by gel electrophoresis of the end products (supplemental Figure 2). A similar extent of TFPI exon 4 deletion was observed with real-time qPCR on genomic DNA from embryos and adult organs.
We used fXa-conjugated beads to pull down TFPI and performed western blot analysis to evaluate the level of full-length protein in adult TFPI_K1δ/δ animals. No full-length TFPI protein was detected in the liver, heart, lung, spleen, kidney, or plasma of TFPI_K1δ/δ mice. Instead, a truncated product corresponding to K1-deleted TFPI was readily observed (Figure 3B). Thus, TFPI_K1δ/δ mice lack detectable full-length TFPI protein expression.
TFPI K1–deficient mice show enhanced thrombin generation and are more susceptible to TF-induced pulmonary embolism
TFPI inhibits TF/FVIIa catalytic activity, and deletion of the Kunitz 1 domain results in loss of this inhibition. We measured the ability of TF and fVIIa to activate fX in vitro in the absence or presence of plasma from TFPI_K1δ/δ or WT mice. This activity assay is sensitive to the presence of rTFPI. Factor X activation was significantly reduced in the presence of plasma from WT C57Bl/6 mice (64.2% ± 11.2% relative to no plasma control), whereas plasma from TFPI_K1δ/δ mice had minimal effect (94.6% ± 5.1% relative to no plasma control) (supplemental Figure 3). We performed thrombin generation assay with platelet-poor plasma from TFPI_K1δ/δ mice and WT controls. TFPI_K1δ/δ mice showed reduced lag time as compared with WT controls (6 ± 0.98 minutes vs 7.9 ± 0.78 minutes; P < .006) and increased total thrombin generation as compared with controls in TF-initiated assays (2700 ± 616 nmol vs 216 ± 187 nmol, in WT controls; P < .0001) (Figure 4A). Notably, upon recalcification, platelet-poor plasma from TFPI_K1δ/δ mice showed background thrombin generation in the absence of any added trigger (875 ± 696 nmol). Background thrombin generation was not observed in recalcified WT plasma without added trigger. These data are consistent with prothrombotic status of TFPI_K1δ/δ mice. Measurement of TAT complexes revealed significantly higher TAT levels in TFPI_K1δ/δ animals as compared with WT C57Bl/6 controls (3.8 ± 0.5 ng/mL vs 6.7 ± 1.9 ng/mL; P = .027) (Figure 4B).
We examined the effects of severe TFPI K1 deficiency on intravascular thrombosis by measuring their susceptibility to TF-induced pulmonary embolism compared with WT C57BL/6 mice. Upon IV injection of TF, 4 out of 4 TFPI_K1δ/δ mice exhibited respiratory arrest within 1 minute. In contrast, 6 of the 7 WT C57BL/6 mice survived beyond 30 minutes; 1 WT C57BL/6 mouse died between 5 and 6 minutes following TF injection (Figure 4C). In addition to the end point of death, we assessed the degree of vascular occlusion of the lungs using Evan’s blue perfusion assay. Lungs were scored for degree of perfusion as previously described.21 Lungs of most WT mice remained patent at the end of 30 minutes’ observation (average score 0.5), whereas most TFPI_ K1δ/δ mice did not take up Evan’s blue (average score 3.5) (Figure 4D; supplemental Figure 4).
Severe deficiency of TFPI K1 domain is associated with fibrin deposits in kidneys and rare instances of widespread brain ischemia
Carstairs’ staining of histological sections of organs from TFPI_K1δ/δ mice revealed fibrin deposits in kidneys of 5 out 7 TFPI_K1δ/δ mice that were examined but not in 5 WT C57BL/6 controls (Figure 5). These results were confirmed with anti-(fibrin)ogen immunostaining (data not shown). Heart, liver, lungs, and spleen appeared unremarkable (data not shown). Of 43 TFPI_K1δ/δ mice that were generated, 4 showed adverse events. Two were found dead during the sixth and ninth weeks, respectively. There was no evidence of overt thrombosis or hemorrhage in postmortem observation. Two others were found hunched, lethargic, trembling, and unable to move during the 14th and 16th weeks of age, respectively. These were euthanized, and organs were collected for qPCR and histological analysis. Interestingly, these mice had ≤1% residual full-length TFPI based on real-time qPCR on genomic DNA from liver and kidneys. Notably, these mice with extremely low TFPI did not have short or curly tails reported for complete absence of TFPI K1 domain.15,23 There were no obvious external signs of thrombosis in either mouse. Histological analysis of organs showed infarcted lesions in the brain in both mice, including in the cerebral cortex, brain stem, and hippocampus. Some lesions were old where neurons were replaced by gliotic scar tissue (Figure 6). Other lesions were estimated to be relatively recent, prior to gliosis and macrophage infiltration (supplemental Figure 5A-B), or showing infiltration of F4/80 positive macrophages (supplemental Figure 5C-F). These observations suggest that brain infarctions were a component of the acute illness observed in these animals. In addition, 1 mouse had an enlarged heart with an organized thrombus that stained positive for neutrophil/granulocyte marker Ly6G (supplemental Figure 6).
TFPI K1–deficient mice exhibit a normal life span and are fertile
Using Kaplan-Meier estimate and log-rank test, the TFPI_K1δ/δ and control TFPI_K1δ/+ mice were found to have a comparable probability of adverse event-free survival analyzed up to 55 weeks (P = .34) (Figure 7). We tested whether TFPI_K1δ/δ mice can carry pregnancies. TFPI_K1δ/δ female mice were mated to WT C57Bl/6 male mice. This generated heterozygous progeny, allowing us to evaluate the effect of maternal TFPI deficiency alone. TFPI_K1δ/δ female mice carried pregnancies successfully with litter sizes of 7.5 ± 1.6 (6 pregnancies of 2 female mice analyzed).
In this study, we maintained TFPI expression in the uteroplacental circulation, but expression of full-length protein was disrupted in the fetoplacental circulation and in the embryo proper. The goal was to determine if this strategy would allow generation of mice that lack full-length TFPI and instead express a truncated protein missing the Kunitz-1 domain. We report that our strategy resulted in 95% to 99% deletion of exon 4 that encodes the Kunitz-1 domain. Mice with severe deficiency of full-length TFPI were viable and physically indistinguishable from their littermates. Most did not develop overt external signs of thrombotic or hemorrhagic episodes. Laboratory measurements revealed significantly elevated plasma TAT levels in TFPI_K1δ/δ mice and increased thrombin generation potential measured in vitro. These mice were more susceptible to TF-induced pulmonary embolism than WT C57BL/6 controls. Histological evaluation and Carstairs’ staining revealed frequent instances of fibrin deposition in their renal medulla. Two instances of severe brain ischemia associated with morbidity were observed among 43 TFPI_K1δ/δ mice generated. These rare instances did not result in statistically significant difference in overall survival of TFPI_K1δ/δ mice compared with TFPI_K1δ/+ controls. Thus, TFPI_K1δ/δ mice lived a normal life span. In addition, TFPI_K1δ/δ female mice showed normal fertility and fecundity.
TF/FVIIa catalytic activity and Par4-mediated platelet activation are important determinants of embryonic lethality of TFPI K1 null mice.16,23,24 Platelets express TFPIα capable of binding early forms of FVa released by activated platelets and inhibiting the initial prothrombinase complex.9,25 Absence of this inhibition could result in local amplification of thrombin generation and platelet-mediated pathology. In the absence of Par4, TFPI K1 null mice show elevated TAT levels, but are protected from platelet activation and do not display overt thrombosis. Our results show that mice expressing 1% to 5% full-length TFPI also exhibit elevated TAT, but nonetheless survive in the presence of fully functional platelets and clotting system. These intriguing results suggest that TF/FVII inhibition provided by as little as 1% to 5% expression of TFPI is sufficient to put brakes on platelet-mediated coagulopathy associated with complete absence of TFPI K1.
The Cre-lox system has been widely used for making tissue-specific knockout mice; Meox2Cre provides an alternative to tetraploid aggregation by deleting LoxP-flanked DNA sequences in the embryo with ≥95% efficiency while maintaining them in the placenta. Although TFPI protein expression was below the limit of detection, residual 1% to 5% expression of full-length transcript was measured by qPCR. The Meox2Cre approach has been previously used by others and us to generate endothelial protein C receptor (PROCR)– and thrombomodulin (THBD)-deficient mice.22,26 In both cases, in utero survival of PROCR- and THBD-deficient mice made by Meox2Cre-Lox genetic approach contrasts with the embryonic loss of corresponding null mice generated by germline gene deletion. Low-level residual expression could, at least in part, be responsible for this contrast. Previous work by Castellino and colleagues has shown that very low expression of PROCR is sufficient for embryonic development and disease-free survival, in contrast to complete embryonic lethality in the absence of PROCR.27 Taken together, it is likely that low-level residual expression of full-length TFPI contributes to embryonic and long-term survival of TFPI_K1δ/δ mice.
About 60% TFPI K1 null mice die between 9.5 and 11.5 days of embryonic development, soon after the formation of the definitive placenta.15 Our results confirm this observation and also corroborate the previous finding that TFPI K1 null embryos show disrupted vascular network in the placenta.16 This defect is corrected in placentas of TFPI_K1δ/δ mice, lending support to the notion that TFPI plays as essential role in the placenta. It, however, remains unclear if maintaining placental expression will be sufficient for survival of embryos with 100% TFPI gene disruption. Absence of FVII prolongs intrauterine survival of TFPI K1 null mice, whereas low TF or absence of Par4 results in live pups and adult mice.16,23,24 In each case, survival of TFPI K1 null mice is accompanied by concomitant reduction or absence of TF, FVII, or Par4 in the embryo. Careful reciprocal crosses and other genetic tools are needed to determine if preventing placental pathology alone will be sufficient to allow in utero development and postnatal survival of mice completely lacking TFPI K1 domain.
Inhibition of TFPI activity is being evaluated as a means to boost thrombin generation to compensate for the lack of FVIII or FIX in hemophilia patients.28-33 Our results suggest that inhibition of TFPI K1 domain alone is sufficient to raise plasma TAT levels and increase the potential for fXa and thrombin generation. These observations lend support to the pursuit of K1-specific inhibition in prevention of bleeding in hemophilia patients.31 Though these therapies do not target complete inhibition, a potential risk is tipping the balance toward clotting. Our work has allowed an evaluation of possible developmental and hemostatic outcomes associated with inhibition of TFPI K1 domain activity in mice. Although severe TFPI K1 deficiency did not result in life-threatening thrombotic or hemorrhagic events, chronic fibrosis was indicated by the presence of frequent fibrin deposits in renal medulla. In addition, these mice could be susceptible to progressively increasing brain ischemia and infarction. Brain hemorrhage and diffuse fibrin deposition were previously reported in TFPI K1 null neonates, which survived embryonic development due to heterozygosity of FVII.24 Interestingly, TFPI K1δ/δ mice and embryos did not show short or curly tails observed in TFPI K1 knockout mice.15,23 We also note that in contrast to TFPI K1δ/δ mice, two-thirds of THBD-deficient mice (generated using the same Meox2Cre strategy) succumbed to neonatal death, and the remaining succumbed to overt thrombosis.22 Thus, the absence of Thbd has a more severe impact on thrombotic propensity in C57BL/6 mice than the absence of TFPI K1 domain.
Our approach has allowed the generation of mice with severe deficiency of full-length TFPI without accompanying genetic alterations in coagulation- or inflammation-related molecules. Previous attempts to make TFPI K1 domain null mice had resulted in embryonic lethality.15 Adult null mice could be obtained if they were concomitantly deficient in TF or Par4, precluding evaluation of lack of TFPI K1 domain alone.16,23 Although overtly normal, mice severely deficient in TFPI K1 domain are prothrombotic. They provide a tool to study the role of TFPI K1 domain in physiological and disease processes, such as pregnancy, sepsis, and response to vascular injury.
The full-text version of this article contains a data supplement.
The authors thank Michelle Bordas for maintaining the murine colony and for help with breeding experiments, Nicholas Martinez for coordinating support from the Mast laboratory, the CRI Histology, Imaging and Pediatric Biobank and Analytical Tissue Core for expert services, and Andrew Webb and Ann Diamond for administrative support.
This work was supported by National Institutes of Health, National Heart, Lung, and Blood Institute grants HL112873 (R.S.) and HL068835 (A.E.M.).
Contribution: M.M.C., Q.Y., M.Z., and R.S. designed and performed experiments and analyzed data; A.Y.P. helped with Kaplan-Meier survival analysis and log-rank test; M.W.L. examined and interpreted brain histology slides; A.E.M. provided critical reagents, protocols, and suggestions; R.S. designed the study, interpreted data, and wrote the manuscript; and all authors reviewed the manuscript.
Conflict-of-interest disclosure: M.Z. is a current employee of MPP Group LLC. M.W.L. receives research support from and is a member of Scientific Advisory Boards for Audentes Therapeutics, Solid Biosciences, and Ichorion Therapeutics and is a consultant for Wave Life Sciences. A.E.M. receives research grant from Novo Nordisk. The remaining authors declare no competing financial interests.
Correspondence: Rashmi Sood, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226; e-mail: firstname.lastname@example.org.
M.M.C., Q.Y., and M.Z. contributed equally to this work.